It has been widely acknowledged that the expression of cell surface low-density lipoprotein receptors (LDLR) is usually upregulated in many cancer cell lines, including breast carcinoma, prostate carcinoma, and HCC (Liang et al., 2017). This evidence concerns the gene LDLR and cancer.